Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Public ClinicalTrials.gov record NCT03504852. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
Study identification
- NCT ID
- NCT03504852
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 331 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2018 (Actual)
- Primary completion
- Sep 13, 2019 (Actual)
- Completion
- Jul 15, 2020 (Actual)
- Last update posted
- Oct 11, 2021
2018 – 2020
United States locations
- U.S. sites
- 38
- U.S. states
- 23
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Birmingham | Alabama | 35205 | — |
| Novartis Investigative Site | Phoenix | Arizona | 85032 | — |
| Novartis Investigative Site | Rogers | Arkansas | 72758 | — |
| Novartis Investigative Site | Irvine | California | 92697 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | Sacramento | California | 95819 | — |
| Novartis Investigative Site | San Diego | California | 92123 | — |
| Novartis Investigative Site | Santa Monica | California | 90404 | — |
| Novartis Investigative Site | Centennial | Colorado | 80111 | — |
| Novartis Investigative Site | Tampa | Florida | 33612 | — |
| Novartis Investigative Site | West Palm Beach | Florida | 33409 | — |
| Novartis Investigative Site | Alpharetta | Georgia | 30022 | — |
| Novartis Investigative Site | Snellville | Georgia | 30078 | — |
| Novartis Investigative Site | Skokie | Illinois | 60077 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | New Albany | Indiana | 47150 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40241 | — |
| Novartis Investigative Site | Owensboro | Kentucky | 42303 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02111 | — |
| Novartis Investigative Site | New Brighton | Minnesota | 55112 | — |
| Novartis Investigative Site | Saint Joseph | Missouri | 64506 | — |
| Novartis Investigative Site | East Windsor | New Jersey | 08520 | — |
| Novartis Investigative Site | Verona | New Jersey | 07044 | — |
| Novartis Investigative Site | Forest Hills | New York | 11375 | — |
| Novartis Investigative Site | New York | New York | 10025 1737 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28277 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Novartis Investigative Site | Fairborn | Ohio | 45324 | — |
| Novartis Investigative Site | Oregon City | Oregon | 97045 | — |
| Novartis Investigative Site | Portland | Oregon | 97210 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29414 | — |
| Novartis Investigative Site | Houston | Texas | 77056 | — |
| Novartis Investigative Site | Mesquite | Texas | 75150 | — |
| Novartis Investigative Site | Pflugerville | Texas | 78660 | — |
| Novartis Investigative Site | San Antonio | Texas | 78218 | — |
| Novartis Investigative Site | Norfolk | Virginia | 23507 | — |
| Novartis Investigative Site | Wenatchee | Washington | 98801 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53717 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03504852, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03504852 live on ClinicalTrials.gov.